Development of metoprolol tartrate extended-release matrix tablet formulations for regulatory policy consideration

Journal of Controlled Release

Volumn 50, Issue 1-3, 1998, Pages 247-256

  Nellore, Ranjani V ^b   Singh Rekhi, Gurvinder ^a   Hussain, Ajaz S ^c   Tillman, Lloyd G ^d   Augsburger, Larry L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b ROCHE BIOSCIENCE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d ISIS PHARMACEUTICALS   (United States)

Author keywords

Dissolution; Extended release; Formulation; Guidance; HPMC; HydrophiIic matrix tablet; Manufacturing; Regulation; Scale Up and post Approval Changes (SUPAC)

Indexed keywords

AEROSIL; CALCIUM PHOSPHATE; CALCIUM PHOSPHATE DIBASIC; ETHYL CELLULOSE; FILLER; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; MAGNESIUM STEARATE; METHYLCELLULOSE; METOPROLOL TARTRATE; MICROCRYSTALLINE CELLULOSE; OPADRY YS 17006; POVIDONE; SILICON DIOXIDE; STEARIC ACID; TALC; UNCLASSIFIED DRUG;

ARTICLE; DISSOLUTION; DRUG GRANULATION; DRUG RELEASE; MATRIX TABLET; PRIORITY JOURNAL; REGULATORY MECHANISM; TABLET COMPRESSION; TABLET FORMULATION; VISCOSITY;

ADRENERGIC BETA-ANTAGONISTS; DELAYED-ACTION PREPARATIONS; DRUG AND NARCOTIC CONTROL; METOPROLOL; TABLETS; VISCOSITY;

EID: 0344474555     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)00141-7     Document Type: Article

References (22)

1. FDA Guidance for industry - Immediate release solid oral dosage forms/scale-up and post approval changes: Chemistry, manufacturing, and controls. In vitro dissolution testing and in vivo bioequivalence documentation. Federal Register. 60(230):1995;61638-61643.
2. Augsburger L.L., Shangraw R.F., Lesko L.J., Williams R. An approach toward establishing a scientific foundation for interpreting regulations and workshop reports on scale-up and post-approval changes. Pharm. Res. 11:1994;S143.
3. Skelly J.P., Van Buskrik G.A., Arbit H.M., Amidon G.L., Augsburger L., Barr W.H., Berge S., Clevenger J., Dighe S., Fawzi M., Fox D., Gonzalez M.A., Gray V.A., Hoiberg C., Leeson L.J., Lesko L., Malinowski H., Nixon P.R., Pearce D.M., Peck G., Porter S., Robinson J., Savello D.R., Schwartz P., Schwartz J.B., Shah V.P., Shangraw R., Theeuwes F., Wheatley T. Scaleup of oral extended-release dosage forms. Pharm. Res. 10:1993;1800-1805.
4. M. Gibaldi, Biopharmaceutics and Clinical Pharmacokinetics, 3rd. ed., Lea and Febiger, Philadelphia, PA, 1984, pp. 113-130.
5. B. Berner, S. Dinh, Fundamental concepts in controlled release, in: A. Kyodenius (Ed.), Treatise on Controlled Delivery, Marcel Dekker Inc., New York, 1992, pp. 1-36.
6. N. Lordi, Sustained release dosage forms, in: L. Lachman, H. Lieberman, J. Kanig (Eds.), The Theory and Practice of Industrial Pharmacy, Lea and Febiger, Philadelphia, PA, 1986, pp. 430-456.
7. Kumar V., Banker G. Chemically-modified cellulosic polymers. Drug Dev. Ind. Pharm. 19:1993;1-31.
8. Melia C.D. Hydrophilic matrix sustained release systems based on polysaccharide carrriers. Crit. Rev. Ther. Drug Carrier Syst. 8:1991;395-421.
9. Dow Pharmaceutical Excipients, The Dow Chemical Company, Midland, Michigan, 1996.
10. Hogan J. Hydroxypropyl methylcellulose sustained release technology. Drug Dev. Ind. Pharm. 15:1989;975-999.
11. Lucisano L., Breech J., Angel L., Franz R. Evaluation of an alternate source of hydroxypropyl methylcellulose for use in a sustained-release tablet matrix. Pharm. Tech. 13:1989;88-98.
12. Ford J., Rubinstein M., Hogan J. Formulation of sustained release promethazine hydrochloride tablets using hydroxypropyl methylcellulose matrices. Int. J. Pharm. 24:1985;327-338.
13. Sarkar N. Thermal gelation properties of methyl and hydroxypropyl methylcellulose. J. Appl. Polym. Sci. 24:1979;1073-1087.
14. Cheong L., Heng P., Wong L. Relationship between polymer viscosity and drug release from a matrix system. Pharm. Res. 9:1992;1510-1514.
15. Ford J., Rubinstein M., Hogan J. Propranolol hydrochloride and aminophylline release from matrix tablets containing hydroxypropyl methylcellulose. Int. J. Pharm. 24:1985;339-350.
16. Lapidus H., Lordi N.G. Drug release from compressed hydrophilic matrices. J. Pharm. Sci. 57:1968;1292-1301.
17. Alderman D.A. A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms. Int. J. Pharm. Tech. Prod. Mfr. 5:1984;1-9.
18. Ragnarsson G., Sandberg A., Jonsson U., Sjogren J. Development of a new controlled release metoprolol product. Drug Dev. Ind. Pharm. 13:1987;1495-1509.
19. Rekhi G.S., Nellore R.V., Tillman L.G., Augsburger L.L. Identification of critical formulation and processing variables for metoprolol tartrate extended-release (ER) matrix tablets. Pharm. Res. 13:1996;S315.
20. Hussain A.S., Eddington N.D., Marroum P., Wang J.T., Shiu G., Mistry B., Leslie J., Rekhi G.S., Augsburger L.L. Artificial neural network (ANN) approach for establishing a predictive relationship between in vitro drug release and in vivo serum drug levels. Pharm. Res. 13:1996;S489.
21. G.S. Rekhi, R.V. Nellore, N.D. Eddington A.S. Hussain, L.G. Tillman, L.L. Augsburger, Effect of scale-up and predictability using neural computing for metoprolol tartrate extended-release tablets, Pharm. Res. 14 (1997).
22. G.S. Rekhi, R.V. Nellore, N.D. Eddington, A.S. Hussain, L.G. Tillman, L.L. Augsburger, Effect of granulation processing changes (fluid-bed vs high-shear vs high-shear microwave) and scale-up on in vitro/in vivo performance for metoprolol tartrate extended-release tablets, Pharm. Res. 14 (1997).